Promoting Convergence of Digital Healthcare and Financial Sectors
Cha Biotech has secured a total investment of 100 billion won from Hanwha General Insurance and Hanwha Life Insurance.
Cha Biotech announced on January 16 that Hanwha General Insurance and Hanwha Life Insurance participated in its third-party paid-in capital increase. The investment amounts to 70 billion won from Hanwha General Insurance and 30 billion won from Hanwha Life Insurance.
The company explained that this investment is part of a collaboration to promote the convergence of insurance and healthcare businesses by combining Cha Bio Group's medical and biotechnology expertise, as well as its artificial intelligence (AI) and data-driven digital healthcare capabilities, with the infrastructure of Hanwha’s financial and insurance companies.
Both parties will jointly develop health management programs for insurance customers and AI- and data-based health monitoring services. They will also gradually identify new business models that link overseas insurance with healthcare.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
